Prevention of paediatric asthma and allergy by reduction of house dust mite content Source: Eur Respir J 2001; 18: Suppl. 33, 287s Year: 2001
House dust mite (HDM) avoidance and treatment of severe childhood asthma Source: Eur Respir J 2003; 22: Suppl. 45, 314s Year: 2003
OPURIT: O malizumab-p rotected u ltra r ush s pecific i mmunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005
House dust mite allergen exposure is associated with sensitisation and asthma in New Zealand infants Source: Eur Respir J 2002; 20: Suppl. 38, 117s Year: 2002
Exposure to higher levels of house dust mite allergen and endotoxin is not associated with respiratory symptoms and severity of AHR in older asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 454s Year: 2002
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Sensitisation to house dust mite: its association with bronchial hyperresponsiveness and lung function in asthmatic children Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009
The association of adult bronchial responsiveness with IgE sensitisation and exposure to cat and house dust mite allergen Source: Eur Respir J 2006; 28: Suppl. 50, 145s Year: 2006
Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Exposure to gas, dust and fumes increases the risk of mite sensitisation and asthma Source: International Congress 2014 – Risk factors for respiratory disease Year: 2014
Concentration of house dust mites, respiratory symptoms and atopy markers Source: Eur Respir J 2005; 26: Suppl. 49, 680s Year: 2005
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
High-altitude treatment in atopic and nonatopic patients with severe asthma Source: Eur Respir J 2012; 40: 1374-1380 Year: 2012
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005
Late Breaking Abstract - Budget impact of introducing 12SQ HDM SLIT-tablet for house dust mite allergic asthma in Spain Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019